These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 31382795)
1. Liposomes: a promising carrier for respiratory syncytial virus therapeutics. Joshi S; Bawage S; Tiwari P; Kirby D; Perrie Y; Dennis V; Singh SR Expert Opin Drug Deliv; 2019 Sep; 16(9):969-980. PubMed ID: 31382795 [No Abstract] [Full Text] [Related]
2. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines. Fuentes S; Arenas D; Moore MM; Golding H; Khurana S Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627 [TBL] [Abstract][Full Text] [Related]
3. Up-to-date role of biologics in the management of respiratory syncytial virus. Boyoglu-Barnum S; Tripp RA Expert Opin Biol Ther; 2020 Sep; 20(9):1073-1082. PubMed ID: 32264720 [TBL] [Abstract][Full Text] [Related]
4. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries. Carbonell-Estrany X; Rodgers-Gray BS; Paes B Expert Rev Anti Infect Ther; 2021 Apr; 19(4):419-441. PubMed ID: 32972198 [TBL] [Abstract][Full Text] [Related]
5. Enhanced immune protection by a liposome-encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids from Deinococcus radiodurans. Huang Y; Anderson R Vaccine; 2002 Feb; 20(11-12):1586-92. PubMed ID: 11858866 [TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus: prospects for new and emerging therapeutics. Jorquera PA; Tripp RA Expert Rev Respir Med; 2017 Aug; 11(8):609-615. PubMed ID: 28574729 [TBL] [Abstract][Full Text] [Related]
7. Emerging small and large molecule therapeutics for respiratory syncytial virus. Bergeron HC; Tripp RA Expert Opin Investig Drugs; 2020 Mar; 29(3):285-294. PubMed ID: 32096420 [No Abstract] [Full Text] [Related]
8. Novel therapies and vaccines against the human respiratory syncytial virus. Rivera CA; Gómez RS; Díaz RA; Céspedes PF; Espinoza JA; González PA; Riedel CA; Bueno SM; Kalergis AM Expert Opin Investig Drugs; 2015; 24(12):1613-30. PubMed ID: 26457559 [TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Broadbent L; Groves H; Shields MD; Power UF Influenza Other Respir Viruses; 2015 Jul; 9(4):169-78. PubMed ID: 25847510 [TBL] [Abstract][Full Text] [Related]
17. New drugs and treatment for respiratory syncytial virus. Maggon K; Barik S Rev Med Virol; 2004; 14(3):149-68. PubMed ID: 15124232 [TBL] [Abstract][Full Text] [Related]
18. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Empey KM; Peebles RS; Kolls JK Clin Infect Dis; 2010 May; 50(9):1258-67. PubMed ID: 20235830 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome. Xu J; Ding Y; Yang Y Viral Immunol; 2008 Dec; 21(4):483-9. PubMed ID: 19115938 [TBL] [Abstract][Full Text] [Related]